<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796300</url>
  </required_header>
  <id_info>
    <org_study_id>UCLA Bioflo 2016</org_study_id>
    <nct_id>NCT02796300</nct_id>
  </id_info>
  <brief_title>Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters</brief_title>
  <official_title>Comparison of the Palindrome vs. BioFlo DuraMax Hemodialysis Catheters: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Angiodynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous catheter designs have been studied to increase efficacy and minimize complications
      of catheter hemodialysis. Major complications of catheters include thrombosis, central venous
      stenosis, infection, and dialysis inadequacy. Thrombosis must be avoided if possible because
      using too many catheters may exhaust all of the catheter insertion sites on the body, as well
      as increase the risk of infection. This prospective study compares the complications and
      general outcomes of patients who receive hemodialysis using the mainstream Palindrome
      catheter versus the newer BioFlo DuraMax catheter.

      This study will examine outcomes of patients who receive hemodialysis using either the
      Palindrome catheter or the BioFlo catheter. Patients will be observed and outcomes will be
      recorded for three to six months. Outcomes will be analyzed and compared to draw conclusions
      on which catheter produces less catheter thrombosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Catheter thrombosis rate of Bioflo catheters vs. Palindrome catheters.</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catheter thrombosis rate of Bioflo catheters vs. Palindrome catheters.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter thrombosis rate of Bioflo catheters vs. Palindrome catheters.</measure>
    <time_frame>6 months</time_frame>
    <description>If necessary, we will monitor the catheter thrombosis rate of Bioflo catheters vs. Palindrome catheters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Analysis</measure>
    <time_frame>3 months</time_frame>
    <description>To perform a cost-analysis and economic burden of using Bioflo catheters compared to Palindrome catheters due to catheter thrombosis and exchange.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Bioflo Goup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will have dialysis using the Bioflo catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palindrome Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will have dialysis using the Palindrome catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioflo Dialysis Catheter</intervention_name>
    <description>The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.</description>
    <arm_group_label>Bioflo Goup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Palindrome Dialysis Catheter</intervention_name>
    <description>The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.</description>
    <arm_group_label>Palindrome Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females 18 - 65 years of age;

          2. First de novo dialysis catheter placement or second catheter exchange, no more than 3
             replacements on a same site

          3. Requiring at least 3 months dialysis catheter usage

          4. No clinical or radiographic evidence of superior vena cava (SVC) narrowing

          5. Patent right internal or external jugular vein

          6. Willing to provide the dialysis center information for F/U

          7. No known diagnosis of hypercoagulopathy

        Exclusion Criteria:

          1. Short term catheter usage plan (&lt; 1 months)

          2. No right jugular venous access

          3. Catheter use for bone marrow transplant or plasmapheresis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria Rueda, MPH</last_name>
    <phone>310-794-8334</phone>
    <email>VRueda@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saima Chaabane, PhD</last_name>
    <phone>310-794-8995</phone>
    <email>schaabane@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Rueda, MPH</last_name>
      <phone>310-794-8334</phone>
      <email>vrueda@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Saima Chaabane, PhD</last_name>
      <phone>310-794-8995</phone>
      <email>schaabane@mednet.ucla.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Edward Wolfgang Lee, MD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>bioflo</keyword>
  <keyword>Duramax catheter</keyword>
  <keyword>dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

